This webinar was sponsored by ThermoFisher Scientific and Johnson&Johnson.
In this webinar, Diego Luigi Cortinovis and Fabio Pagni, University of Milano-Bicocca, Italy, provide an in-depth overview of the latest advancements in precision therapy for NSCLC and the importance of rapid biomarker profiling for timely therapeutic decisions.
Topics covered:
- Overview of precision medicine in NSCLC and current biomarker testing needs: an oncologist’s perspective
- Discussing the significance of rapid biomarker profiling, and why in 2024 we should consider NGS for timely therapeutic decision-making: a pathologist’s perspective
- Evaluating the cost-effectiveness and real-world outcomes of NGS in NSCLC
Speakers
Diego Luigi Cortinovis1
Fabio Pagni2
- Professor of Medical Oncology and Vice-Director, Department of Medical Oncology, San Gerardo Hospital, Monza, Italy; and School of Medicine and Surgery, University of Milano-Bicocca, Italy
- Professor of Pathology,Department of Medicine and Surgery, Pathology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
Moderator:
Hannah Moir3
3. Head Medical Writer, Moderator, and Educator, EMJ, London, UK. Senior Fellow (Associate Professor in Health & Exercise Prescription), Faculty of Health, Science, Social Care and Education, Kingston University, London, UK.
